Insights,
Roche spends $1 billion on Foundation Medicine’s tumor profiling
Roche spends $1 billion on Foundation Medicine’s tumor profiling
[el-text]
With companion diagnostics’ growing importance in the development of precision medicines, pharma’s interest in gaining stakes in diagnostics companies makes sense. “Pharma companies are deep-pocketed partners with a great deal of FDA experience, and the agency eventually wants to regulate LDTs,” says Marc Samuels, president and CEO of ADVI, a Washington, DC–based healthcare advisory services firm. “Greater ownership of a diagnostics firm allows a pharma to better manage and control the fate of its pipeline in an era where biomarkers are the key to faster approvals with smaller clinical trials.”
[/el-text]
[el-text]